Actively Recruiting
HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer
Led by Jiangsu HengRui Medicine Co., Ltd. · Updated on 2024-05-09
778
Participants Needed
1
Research Sites
133 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to look at the efficacy and safety of HR070803 in combination with 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer.
CONDITIONS
Official Title
HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- ECOG performance status 0 or 1
- Histologically or cytologically confirmed pancreatic cancer not previously treated for metastatic disease
- Life expectancy of at least 3 months
- At least one measurable lesion according to RECIST 1.1 criteria
- Able and willing to provide written informed consent
You will not qualify if you...
- Pancreatic cancer originating from extrapancreatic ductal epithelium, including neuroendocrine carcinoma, acinar cell carcinoma, pancreatoblastoma, or solid-pseudopapillary tumor
- Known history of central nervous system metastases
- Severe infection (greater than CTCAE grade 2) requiring inpatient treatment within four weeks before enrollment or intravenous antibiotics within two weeks
- Uncontrolled cardiac symptoms or diseases, including NYHA class 2 or higher heart failure, unstable angina, recent myocardial infarction within 6 months, or significant arrhythmias requiring treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
Research Team
J
Jun Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here